These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19359538)

  • 1. Dual antiplatelet drug resistance is a risk factor for cardiovascular events after percutaneous coronary intervention.
    Ivandic BT; Sausemuth M; Ibrahim H; Giannitsis E; Gawaz M; Katus HA
    Clin Chem; 2009 Jun; 55(6):1171-6. PubMed ID: 19359538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy.
    Neubauer H; Kaiser AF; Endres HG; Krüger JC; Engelhardt A; Lask S; Pepinghege F; Kusber A; Mügge A
    BMC Med; 2011 Jan; 9():3. PubMed ID: 21226927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.
    Gori AM; Marcucci R; Migliorini A; Valenti R; Moschi G; Paniccia R; Buonamici P; Gensini GF; Vergara R; Abbate R; Antoniucci D
    J Am Coll Cardiol; 2008 Aug; 52(9):734-9. PubMed ID: 18718420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble P-selectin level correlates with acetylsalicylic acid but not with clopidogrel response in patients with stable coronary artery disease after a percutaneous coronary intervention.
    Kaufmann J; Wellnhofer E; Kappert K; Urban D; Meyborg H; Hauptmann T; Müller A; Meixner M; Graf K; Fleck E; Stawowy P
    Coron Artery Dis; 2013 Jun; 24(4):312-20. PubMed ID: 23549485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor.
    Ivandic BT; Schlick P; Staritz P; Kurz K; Katus HA; Giannitsis E
    Clin Chem; 2006 Mar; 52(3):383-8. PubMed ID: 16423907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
    Cardiovasc Ther; 2016 Aug; 34(4):209-15. PubMed ID: 27086085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation.
    Eshtehardi P; Windecker S; Cook S; Billinger M; Togni M; Garachemani A; Meier B; Hess OM; Wenaweser P
    Am Heart J; 2010 May; 159(5):891-898.e1. PubMed ID: 20435201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
    Morel O; Viellard C; Faure A; Jesel L; Ohlmann P; Desprez D; Chauvin M; Roul G; Grunebaum L; Bareiss P
    Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):21-9. PubMed ID: 17343035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of aspirin responsiveness by use of whole blood platelet aggregometry.
    Ivandic BT; Giannitsis E; Schlick P; Staritz P; Katus HA; Hohlfeld T
    Clin Chem; 2007 Apr; 53(4):614-9. PubMed ID: 17332149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
    Am J Cardiol; 2006 Jan; 97(1):38-43. PubMed ID: 16377281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention: The RECLOSE-3 Study (REsponsiveness to CLOpidogrel and StEnt Thrombosis).
    Valenti R; Marcucci R; Comito V; Marrani M; Cantini G; Migliorini A; Parodi G; Gensini GF; Abbate R; Antoniucci D
    JACC Cardiovasc Interv; 2015 Oct; 8(12):1563-70. PubMed ID: 26386764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
    Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.
    Karolczak K; Kamysz W; Karafova A; Drzewoski J; Watala C
    Pharmacol Res; 2013 Aug; 74():7-22. PubMed ID: 23665469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    Steinhubl SR; Berger PB; Mann JT; Fry ET; DeLago A; Wilmer C; Topol EJ;
    JAMA; 2002 Nov; 288(19):2411-20. PubMed ID: 12435254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
    Stuckey TD; Kirtane AJ; Brodie BR; Witzenbichler B; Litherland C; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Mehran R; Généreux P; Ben-Yehuda O; Simonton CA; Stone GW;
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1607-1617. PubMed ID: 28780034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent clinical trial results with antiplatelet therapy: implications in stroke prevention.
    Teal PA
    Cerebrovasc Dis; 2004; 17 Suppl 3():6-10. PubMed ID: 14730252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
    Nardin M; Verdoia M; Sartori C; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    J Cardiovasc Pharmacol; 2015 Oct; 66(4):364-70. PubMed ID: 26065844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
    Moerenhout CM; Claeys MJ; Haine S; Miljoen H; Bosmans JM; Vertessen F; Kluppels K; Van der Planken M; Vrints CJ
    Am Heart J; 2010 Mar; 159(3):434-8. PubMed ID: 20211306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
    Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
    JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.
    Gajos G; Rostoff P; Undas A; Piwowarska W
    J Am Coll Cardiol; 2010 Apr; 55(16):1671-8. PubMed ID: 20394870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.